Biogen
NEWS
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
The company indicated it is shutting down its gosuranemab program for PSP and other primary tauopathies.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
Biogen’s plan to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease is being met with hope for a needed therapy for a dreaded disease, but also some skepticism regarding its long-term efficacy and, ultimately, potential.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
The pharmaceutical company, Biogen presented further analysis from two phase III trials of the potential new Alzheimer’s drug, aducanumab.
Biogen presented full data today on its Alzheimer’s drug aducanumab at the 12th Clinical Trials on Alzheimer’s Disease conference held in San Diego.
Researchers from around the world are coming to present scientific research and clinical trial data for the disease.
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
JOBS
IN THE PRESS